Lactobacillus casei Shirota protects from fructose-induced liver steatosis: A mouse model

Journal of Nutritional Biochemistry

Volumn 24, Issue 3, 2013, Pages 531-538

  Wagnerberger, Sabine ^a   Spruss, Astrid ^a   Kanuri, Giridhar ^a   Stahl, Carolin ^a   Schröder, Markus ^a   Vetter, Walter ^a   Bischoff, Stephan C ^a   Bergheim, Ina ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Fatty liver; Fructose; Lactobacillus casei Shirota; PPAR ; TLR 4

Indexed keywords

ALANINE AMINOTRANSFERASE; FRUCTOSE; OCCLUDIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; INTESTINE; LACTOBACILLUS CASEI; LIVER; MICROFLORA; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN;

ALANINE TRANSAMINASE; ANIMALS; BUTYRATES; CELL LINE; CELL PROLIFERATION; CHROMANS; DISEASE MODELS, ANIMAL; DNA FINGERPRINTING; DNA, BACTERIAL; FATTY LIVER; FRUCTOSE; HYPOGLYCEMIC AGENTS; INTESTINES; LACTOBACILLUS CASEI; LIVER; MICE; MICE, INBRED C57BL; PPAR GAMMA; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

LACTOBACILLUS CASEI; MUS;

EID: 84875496910     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.01.014     Document Type: Article

References (36)

1. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42(1):44-52.
2. Spruss A., Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 2009, 20(9):657-662.
3. Bode C., Kugler V., Bode J.C. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987, 4(1):8-14.
4. Farhadi A., Gundlapalli S., Shaikh M., Frantzides C., Harrell L., Kwasny M.M., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28(7):1026-1033.
5. Harte A.L., da Silva N.F., Creely S.J., McGee K.C., Billyard T., Youssef-Elabd E.M. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010, 7:15.
6. Soza A., Riquelme A., Gonzalez R., Alvarez M., Perez-Ayuso R.M., Glasinovic J.C., et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005, 50(6):1136-1140.
7. Thuy S., Ladurner R., Volynets V., Wagner S., Strahl S., Konigsrainer A., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008, 138(8):1452-1455.
8. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48(2):206-211.
9. Bergheim I., Weber S., Vos M., Kramer S., Volynets V., Kaserouni S., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008, 48(6):983-992.
10. Cani P.D., Neyrinck A.M., Fava F., Knauf C., Burcelin R.G., Tuohy K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50(11):2374-2383.
11. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37(2):343-350.
12. Esposito E., Iacono A., Bianco G., Autore G., Cuzzocrea S., Vajro P., et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009, 139(5):905-911.
13. Iacono A., Raso G.M., Canani R.B., Calignano A., Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011, 22(8):699-711.
14. O'Hara A.M., Shanahan F. Mechanisms of action of probiotics in intestinal diseases. Sci World J 2007, 7:31-46.
15. Kanuri G., Weber S., Volynets V., Spruss A., Bischoff S.C., Bergheim I. Cinnamon extract protects against acute alcohol-induced liver steatosis in mice. J Nutr 2009, 139(3):482-487.
16. Spruss A., Kanuri G., Wagnerberger S., Haub S., Bischoff S.C., Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50(4):1094-1104.
17. Niscigorska-Olsen J., Wodecka B., Moranska I., Skotarczak B. Genospecies of Borrelia burgdorferi sensu lato in patients with erythema migrans. Ann Agric Environ Med 2008, 15(1):167-170.
18. Christensen J.E., Stencil J.A., Reed K.D. Rapid identification of bacteria from positive blood cultures by terminal restriction fragment length polymorphism profile analysis of the 16S rRNA gene. J Clin Microbiol 2003, 41(8):3790-3800.
19. Kanuri G., Spruss A., Wagnerberger S., Bischoff S.C., Bergheim I. Role of tumor necrosis factor alpha (TNFalpha) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2010.
20. Armutcu F., Coskun O., Gurel A., Kanter M., Can M., Ucar F., et al. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem 2005, 38(6):540-547.
21. Haub S., Kanuri G., Volynets V., Brune T., Bischoff S.C., Bergheim I. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol 2010, 298(3):G335-G344.
22. Matsumoto K., Takada T., Shimizu K., Moriyama K., Kawakami K., Hirano K., et al. Effects of a probiotic fermented milk beverage containing Lactobacillus casei strain Shirota on defecation frequency, intestinal microbiota, and the intestinal environment of healthy individuals with soft stools. J Biosci Bioeng 2010, 110(5):547-552.
23. Park S.Y., Baik Y.H., Cho J.H., Kim S., Lee K.S., Han J.S. Inhibition of lipopolysaccharide-induced nitric oxide synthesis by nicotine through S6K1-p42/44 MAPK pathway and STAT3 (Ser 727) phosphorylation in Raw 264.7 cells. Cytokine 2008, 44(1):126-134.
24. Miele L., Valenza V., La T.G., Montalto M., Cammarota G., Ricci R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49(6):1877-1887.
25. Ackerman Z., Oron-Herman M., Grozovski M., Rosenthal T., Pappo O., Link G., et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005, 45(5):1012-1018.
26. Jurgens H., Haass W., Castaneda T.R., Schurmann A., Koebnick C., Dombrowski F., et al. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res 2005, 13(7):1146-1156.
27. Nissen L., Chingwaru W., Sgorbati B., Biavati B., Cencic A. Gut health promoting activity of new putative probiotic/protective Lactobacillus spp. strains: a functional study in the small intestinal cell model. Int J Food Microbiol 2009, 135(3):288-294.
28. Naito E., Yoshida Y., Makino K., Kounoshi Y., Kunihiro S., Takahashi R., et al. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011, 110(3):650-657.
29. Stadlbauer V., Mookerjee R.P., Hodges S., Wright G.A., Davies N.A., Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008, 48(6):945-951.
30. De Preter V., Vanhoutte T., Huys G., Swings J., De Vuyst L., Rutgeerts P., et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 2007, 292(1):G358-G368.
31. Avella M.A., Olivotto I., Silvi S., Place A.R., Carnevali O. Effect of dietary probiotics on clownfish: a molecular approach to define how lactic acid bacteria modulate development in a marine fish. Am J Physiol Regul Integr Comp Physiol 2010, 298(2):R359-R371.
32. Ohashi Y., Tokunaga M., Ushida K. The effect of Lactobacillus casei strain Shirota on the cecal fermentation pattern depends on the individual cecal microflora in pigs. J Nutr Sci Vitaminol (Tokyo) 2004, 50(6):399-403.
33. Ji Y., Liu J., Wang Z., Liu N., Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest 2009, 89(8):887-902.
34. Wu Y., Zhao X.D., Zhuang Z., Xue Y.J., Cheng H.L., Yin H.X., et al. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells. Brain Res 2010, 1322:102-108.
35. Zhang F., Liu F., Yan M., Ji H., Hu L., Li X., et al. Peroxisome proliferator-activated receptor-gamma agonists suppress iNOS expression induced by LPS in rat primary Schwann cells. J Neuroimmunol 2010, 218(1-2):36-47.
36. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122(5):707-721.